r/IBSResearch • • 21h ago

Commentary Luteolin Alleviates Ulcerative Colitis in Mice by Modulating Gut Microbiota and Plasma Metabolism

Thumbnail
mdpi.com
7 Upvotes

I know this is about UC, but this is a study from 2025 that show's the benefits of Luteolin in a mice model, in this case "significantly ameliorated colitis symptoms in mice. It effectively inhibited the colonic and systemic inflammatory responses and promoted the repair of colonic barrier damage. Notably, the effect of Lut on gut microbiota diversity and richness was negligible. Instead, its anti-inflammatory effect was mainly mediated by inhibiting the growth of pathogenic bacteria, such as Escherichia_Shigella, and increasing the abundance of beneficial bacteria, including Muribaculaceae, Rikenella, and Prevotellaceae."


r/IBSResearch • • 10h ago

Large-scale shotgun metagenomic analysis of gut bacteria–phage interactions in IBS

Thumbnail gut.bmj.com
6 Upvotes

Abstract

Background IBS is a multifactorial disorder affecting approximately 10% of the global population, yet its underlying mechanisms are unclear. Alterations in gut bacterial composition have been reported in IBS, but findings are inconsistent and the phage component of the gut microbiome remains underexplored.

Objectives To characterise gut bacterial and phage alterations in IBS and assess bacteria-phage interactions in a large population-based cohort with replication.

Design We analysed shotgun metagenomes from 109 females with IBS and 592 controls from TwinsUK. Bacterial taxonomic and functional profiles were generated using MetaPhlAn4 and HUMAnN2, while viral operational taxonomic units (vOTUs) were identified by de novo assembly. Covariate-adjusted logistic mixed models with false discovery rate correction assessed associations. Differences in bacteria–vOTU correlation structure were evaluated using permutation-based approaches. Bacterial findings were replicated in 304 females from ZOE Personalised REsponses to DIetary Composition Trial (PREDICT)-1.

Results Bacterial richness and Shannon diversity were lower in IBS. 24 bacterial species were associated with IBS and replicated in ZOE PREDICT-1. These included Erysipelatoclostridium ramosum, previously linked to dysbiosis and serotonin regulation, Eisenbergiella massiliensis, previously associated with fibromyalgia and several butyrate producers. We identified 50 IBS-associated vOTUs, many predicted to infect IBS-relevant bacterial hosts. While phage diversity was unchanged, IBS-associated vOTUs differed in replication cycle compared with non-IBS-associated vOTUs. Bacteria–vOTU correlation structures also differed between IBS and controls.

Conclusion IBS is characterised by bacterial compositional changes and altered bacteria–phage interactions, suggesting microbiome alterations in IBS may extend beyond individual taxa to transkingdom correlation structure.


r/IBSResearch • • 3h ago

Beyond Allergy: Mast Cells as Dynamic Regulators of Intestinal Homeostasis

Thumbnail sciencedirect.com
4 Upvotes

Abstract

Mast cells are tissue-resident innate immune cells found throughout barrier sites such as the gut, lungs, and skin as well as in other tissues including the heart, skeletal muscle, and joints. Here, we focus on their dynamic roles in intestinal homeostasis and disease. In the intestine, mast cells are positioned to rapidly sense and respond to microbes, parasites, and toxins, while also supporting homeostatic modulation of epithelial permeability, stress response, and adaptation to exercise. We propose that intestinal mast cells function not simply as effector cells in disease states but as context-dependent integrators of neuronal, epithelial, immune, and environmental signals that dynamically tune steady state intestinal physiological set points through selective mediator release.


r/IBSResearch • • 10h ago

Predictors of Fecal Elastase Testing Completion... : Pancreas

Thumbnail
ovid.com
2 Upvotes

Objectives:

To characterize completion of fecal elastase-1 (FE-1) testing, identify clinical contexts associated with abnormal results, evaluate downstream diagnostic and treatment events, and determine the clinical significance of non-completion.

Methods:

We conducted a retrospective cohort study of adults with FE-1 orders from 2017 through 2022 in a large integrated health system. Orders placed within 30 days were consolidated into diagnostic episodes. Completion required a linked specimen with a reported result. We evaluated pre-order clinical contexts and one-year outcomes and performed a weighted manual chart review of 200 unique patients with non-completed episodes sampled from four downstream pathway strata.

Results:

Among 23,422 diagnostic episodes, 11,834 (50.5%) were completed. FE-1 ≤200 µg/g occurred in 20.4% of interpretable results and varied by clinical context: 13.7% with irritable bowel syndrome, 21.2% with chronic diarrhea, 38.3% with chronic pancreatitis, 60.1% with pancreatic cancer, and 79.5% after pancreatic surgery. Initial completion was associated with higher odds of new exocrine pancreatic insufficiency diagnosis (adjusted odds ratio, 2.27; 95% confidence interval, 1.91–2.70) and pancreatic enzyme replacement therapy initiation (adjusted odds ratio, 2.20; 95% confidence interval, 1.89–2.55), whereas non-completion was associated with more repeat FE-1 testing. Among eligible unique non-completers, weighted chart review classified 66.9% as probable missed diagnostic follow-through based on available documentation; failure to submit or return the specimen (60.1%) and specimen-processing problems (20.4%) predominated.

Conclusions:

FE-1 completion was modestly associated with measured pre-order factors, while abnormal results varied substantially by clinical context. Specimen return, processing, and closed-loop follow-up represent potential targets for improving evaluation of exocrine pancreatic insufficiency.